CL2011000050A1 - Forma de dosificacion para administracion por inhalacion oral que comprende aglomerados de 400 y 700 micrones de particulas de un tamaño = 10 um de un agente activo y de un aglutinante solido cristalino, teniendo los aglomerados una densidad global de 0,3-0,4 g/cm3 y una fuerza de quiebre de 200-1.500 mg (divisional solicitud 568-98). - Google Patents

Forma de dosificacion para administracion por inhalacion oral que comprende aglomerados de 400 y 700 micrones de particulas de un tamaño = 10 um de un agente activo y de un aglutinante solido cristalino, teniendo los aglomerados una densidad global de 0,3-0,4 g/cm3 y una fuerza de quiebre de 200-1.500 mg (divisional solicitud 568-98).

Info

Publication number
CL2011000050A1
CL2011000050A1 CL2011000050A CL2011000050A CL2011000050A1 CL 2011000050 A1 CL2011000050 A1 CL 2011000050A1 CL 2011000050 A CL2011000050 A CL 2011000050A CL 2011000050 A CL2011000050 A CL 2011000050A CL 2011000050 A1 CL2011000050 A1 CL 2011000050A1
Authority
CL
Chile
Prior art keywords
agglomerates
microns
particles
dosage form
divisional application
Prior art date
Application number
CL2011000050A
Other languages
English (en)
Inventor
Yang Tsong-Toh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25232603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2011000050A1 publication Critical patent/CL2011000050A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forma de dosificación de un agente farmacológico para inhalación oral que comprende aglomerados de partículas entre 400 y 700 micrones, y partículas de aglutinante sólido cristalino de tamaño promedio de 10 micrones o menor, donde la proporción agente farmacológico: Aglutinante es 100:1 a 1:500 (Divisional Solicitud 568-98).
CL2011000050A 1997-03-20 2011-01-10 Forma de dosificacion para administracion por inhalacion oral que comprende aglomerados de 400 y 700 micrones de particulas de un tamaño = 10 um de un agente activo y de un aglutinante solido cristalino, teniendo los aglomerados una densidad global de 0,3-0,4 g/cm3 y una fuerza de quiebre de 200-1.500 mg (divisional solicitud 568-98). CL2011000050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82112997A 1997-03-20 1997-03-20

Publications (1)

Publication Number Publication Date
CL2011000050A1 true CL2011000050A1 (es) 2011-06-24

Family

ID=25232603

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000050A CL2011000050A1 (es) 1997-03-20 2011-01-10 Forma de dosificacion para administracion por inhalacion oral que comprende aglomerados de 400 y 700 micrones de particulas de un tamaño = 10 um de un agente activo y de un aglutinante solido cristalino, teniendo los aglomerados una densidad global de 0,3-0,4 g/cm3 y una fuerza de quiebre de 200-1.500 mg (divisional solicitud 568-98).

Country Status (26)

Country Link
EP (3) EP0969816B1 (es)
JP (5) JP3901738B2 (es)
KR (1) KR100386055B1 (es)
CN (3) CN100548277C (es)
AR (1) AR011986A1 (es)
AT (2) ATE415149T1 (es)
AU (1) AU741783B2 (es)
CA (3) CA2706634C (es)
CL (1) CL2011000050A1 (es)
CZ (1) CZ295460B6 (es)
DE (2) DE69840277D1 (es)
DK (2) DK1393721T3 (es)
ES (2) ES2316681T3 (es)
HK (2) HK1021323A1 (es)
HU (2) HU226671B1 (es)
ID (1) ID24472A (es)
IL (1) IL131640A0 (es)
MY (1) MY120725A (es)
NO (1) NO328062B1 (es)
NZ (1) NZ337443A (es)
PL (3) PL192441B1 (es)
PT (2) PT969816E (es)
SK (1) SK284919B6 (es)
TW (1) TWI221778B (es)
WO (1) WO1998041193A1 (es)
ZA (1) ZA982254B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6623760B1 (en) 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
JP2003526629A (ja) * 1999-08-20 2003-09-09 ノートン ヘルスケアー リミテッド 経肺または経鼻投与のための粉末の製造法
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007501194A (ja) * 2003-08-05 2007-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ステロイドとβ模倣薬を含む吸入用薬剤
EP1667687A1 (en) * 2003-09-26 2006-06-14 Schering Corporation Pulmonary disease treatment
CA2543482A1 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
PT1691787E (pt) * 2003-12-04 2008-09-02 Pfizer Prod Inc Método de formação de multipartículas farmacêuticas
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
IL168603A (en) * 2005-05-16 2011-05-31 Resdevco Res And Dev Co Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
TW201024034A (en) 2008-12-30 2010-07-01 Saint Gobain Abrasives Inc Bonded abrasive tool and method of forming
AU2010238641A1 (en) * 2009-04-24 2011-11-10 Merck Sharp & Dohme Corp. Agglomerate formulations useful in dry powder inhalers
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2763939A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
SI2560611T1 (en) * 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. A process for preparing particles with reduced electrostatic charges
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
JP6020489B2 (ja) 2014-02-27 2016-11-02 トヨタ自動車株式会社 昇圧コンバータ及びその制御方法
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
MX2018008348A (es) * 2016-01-08 2018-12-06 Theron Pharmaceuticals Inc Composiciones de inhalador de polvo seco de derivados de 7-azoniabiciclo[2.2.1]heptano.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
ES2044710T3 (es) * 1990-01-29 1994-01-01 Ciba Geigy Ag Procedimiento y dispositivo de dosificacion de un polvo de granulometria fina.
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
MY115140A (en) 1992-12-18 2003-04-30 Schering Corp Inhaler for powdered medications
HU222355B1 (hu) * 1993-10-01 2003-06-28 Astra Aktiebolag Eljárás és berendezés finom gyógyszerhatóanyag-porok kezelésére és feldolgozására
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
KR100389080B1 (ko) * 1994-12-22 2003-10-17 아스트라제네카 악티에볼라그 부갑상선호르몬(pth)을포함하는흡입용치료제제

Also Published As

Publication number Publication date
IL131640A0 (en) 2001-01-28
HUP0002029A3 (en) 2001-02-28
AU6537898A (en) 1998-10-12
CN1903179A (zh) 2007-01-31
DE69840277D1 (de) 2009-01-08
HU0600845D0 (en) 2007-01-29
CA2282360C (en) 2004-11-09
SK284919B6 (sk) 2006-02-02
ZA982254B (en) 1998-09-17
PL335742A1 (en) 2000-05-08
PL192441B1 (pl) 2006-10-31
AR011986A1 (es) 2000-09-13
MY120725A (en) 2005-11-30
JP2010275316A (ja) 2010-12-09
CN100518718C (zh) 2009-07-29
CN1257423A (zh) 2000-06-21
JP5523240B2 (ja) 2014-06-18
CN1149076C (zh) 2004-05-12
PL204480B1 (pl) 2010-01-29
CZ295460B6 (cs) 2005-08-17
PT1393721E (pt) 2009-02-02
HUP0002029A2 (hu) 2000-11-28
JP2010248260A (ja) 2010-11-04
ATE284677T1 (de) 2005-01-15
KR100386055B1 (ko) 2003-06-09
EP2036544B1 (en) 2016-12-28
CA2706634C (en) 2012-10-23
CA2481868C (en) 2010-06-15
NZ337443A (en) 2001-04-27
NO994519L (no) 1999-11-19
DK1393721T3 (da) 2009-03-30
ES2234102T3 (es) 2005-06-16
HU226671B1 (en) 2009-06-29
EP2036544A1 (en) 2009-03-18
JP3901738B2 (ja) 2007-04-04
EP0969816A1 (en) 2000-01-12
PL208480B1 (pl) 2011-05-31
JP2000510478A (ja) 2000-08-15
WO1998041193A1 (en) 1998-09-24
CZ323399A3 (cs) 2000-02-16
EP0969816B1 (en) 2004-12-15
DK0969816T3 (da) 2005-03-14
CA2282360A1 (en) 1998-09-24
EP1393721B1 (en) 2008-11-26
NO328062B1 (no) 2009-11-13
HK1021323A1 (en) 2000-06-09
KR20010005520A (ko) 2001-01-15
AU741783B2 (en) 2001-12-06
ID24472A (id) 2000-07-20
SK128099A3 (en) 2000-06-12
CN100548277C (zh) 2009-10-14
DE69828155T2 (de) 2005-12-22
CA2481868A1 (en) 1998-09-24
HK1061359A1 (en) 2004-09-17
HU230274B1 (hu) 2015-11-30
CA2706634A1 (en) 1998-09-24
JP2014037446A (ja) 2014-02-27
EP1393721A1 (en) 2004-03-03
CN1552310A (zh) 2004-12-08
ES2316681T3 (es) 2009-04-16
DE69828155D1 (de) 2005-01-20
PT969816E (pt) 2005-04-29
TWI221778B (en) 2004-10-11
JP2006152000A (ja) 2006-06-15
NO994519D0 (no) 1999-09-17
ATE415149T1 (de) 2008-12-15

Similar Documents

Publication Publication Date Title
CL2011000050A1 (es) Forma de dosificacion para administracion por inhalacion oral que comprende aglomerados de 400 y 700 micrones de particulas de un tamaño = 10 um de un agente activo y de un aglutinante solido cristalino, teniendo los aglomerados una densidad global de 0,3-0,4 g/cm3 y una fuerza de quiebre de 200-1.500 mg (divisional solicitud 568-98).
BR9911070A (pt) Sistema de liberação de droga compreendendo uma matéria-prima de medicamento sólido acentuadamente compacto
ES2036457B1 (es) Forma de dosificacion farmaceutica solida oral de liberacion programada y procedimiento de preparacion.
BR0005938A (pt) Composição de dosagem oral com libaraçãoprolongada
BR9909266A (pt) Formulações efervescentes
BR9914251A (pt) Formulações orais de liberação sustentada
DE69601158D1 (de) Zusammensetzungen enthaltend nsaid-nanopartikel
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
BR9807368A (pt) Comprimidos de oxacarvazepina revestidos com pelìcula
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
ES2193726T3 (es) Formulaciones de aerosol medicinales.
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
NZ337345A (en) Pharmaceutical compositions for controlled release of active substances comprising an alkalinizing agent
AU1537095A (en) Therapeutic agents containing thyroid hormones
TR200100569T2 (tr) Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
ES8100077A1 (es) Procedimiento para preparar pastillas de glucosidos cardioactivos
ES2149082B1 (es) Nueva formulacion para inhalacion.
ES2148059B1 (es) Nueva formulacion para inhalacion.
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
CO4940406A1 (es) Composiciones de paracetamol de accion rapida
BR0012444A (pt) Composições de pó seco
ES8307496A1 (es) Procedimiento para la obtencion de una preparacion galenica antagonista al calcio.